Clinical Trials | May 25, 2026
AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Expands Davaindia network to 2,579 stores
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The approval was granted by Agenzia Italiana del Farmaco
Subscribe To Our Newsletter & Stay Updated
